COVID-19 is an emerging, rapidly evolving situation. doi: 10.1002/14651858.CD012615.pub2.Caldwell PH, Codarini M, Stewart F, Hahn D, Sureshkumar P.Cochrane Database Syst Rev. 6 years or older: 0.2 to 0.6 mg orally once daily before bedtime. Preoperative IV doses may be given 30 minutes prior to scheduled procedure. The reduction in nocturnal diuresis occurred almost exclusively in the group with a nocturnal urinary output of ≥1.3 mL/min. Comparison 3 Desmopressin versus alpha‐blocker, Outcome 3 Major adverse events (short term). Select one or more newsletters to continue. 2017 Nov 22;11(11):CD012615. 2020 May 4;5(5):CD002911. Please enable it to take advantage of the complete set of features! doi: 10.1002/14651858.CD012059.pub2. This study included data from 136 men over the age of 65 with nocturia from different causes. Liver Dose Adjustments. Risk of bias summary: review authors' judgments about each risk of bias item for each included study.Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies.Comparison 1 Desmopressin versus placebo, Outcome 1 Number of nocturnal voids (short term) (subgroup route).Comparison 1 Desmopressin versus placebo, Outcome 2 Number of nocturnal voids (intermediate term).Comparison 1 Desmopressin versus placebo, Outcome 3 Major adverse events (short term) (subgroup route and dose).Comparison 1 Desmopressin versus placebo, Outcome 4 Major adverse events (intermediate term).Comparison 1 Desmopressin versus placebo, Outcome 5 Duration of first sleep episode (short term).Comparison 1 Desmopressin versus placebo, Outcome 6 Duration of first sleep episode (intermediate term).Comparison 1 Desmopressin versus placebo, Outcome 7 Time to first void (short term) [minutes].Comparison 1 Desmopressin versus placebo, Outcome 8 Minor adverse events (short term).Comparison 1 Desmopressin versus placebo, Outcome 9 Minor adverse events (intermediate term).Comparison 1 Desmopressin versus placebo, Outcome 10 Treatment withdrawal due to adverse event (short term).Comparison 1 Desmopressin versus placebo, Outcome 11 Treatment withdrawal due to adverse event (intermediate term).Comparison 1 Desmopressin versus placebo, Outcome 12 Number of nocturnal voids (short term) (subgroup dose).Comparison 1 Desmopressin versus placebo, Outcome 13 Number of nocturnal voids (short term) (subgroup nocturnal polyuria).Comparison 1 Desmopressin versus placebo, Outcome 14 Number of nocturnal voids (short term) (sensitivity run‐in period).Comparison 1 Desmopressin versus placebo, Outcome 15 Major adverse events (short term) (sensitivity run‐in period).Comparison 1 Desmopressin versus placebo, Outcome 16 Number of nocturnal voids (short term) (sensitivity clinical dosage).Comparison 1 Desmopressin versus placebo, Outcome 17 Major adverse events (short term) (sensitivity clinical dosage).Comparison 2 Desmopressin versus behaviour modification, Outcome 1 Duration of first sleep episode (short term).Comparison 3 Desmopressin versus alpha‐blocker, Outcome 1 Number of nocturnal voids (short term).Comparison 3 Desmopressin versus alpha‐blocker, Outcome 2 Quality of life (short term).Comparison 3 Desmopressin versus alpha‐blocker, Outcome 3 Major adverse events (short term).Comparison 3 Desmopressin versus alpha‐blocker, Outcome 4 Minor adverse events (short term).Comparison 3 Desmopressin versus alpha‐blocker, Outcome 5 Treatment withdrawal due to adverse event (short term).Comparison 4 Desmopressin plus alpha‐blocker versus alpha‐blocker, Outcome 1 Number of nocturnal voids (short term) (subgroup route and dose).Comparison 4 Desmopressin plus alpha‐blocker versus alpha‐blocker, Outcome 2 Number of nocturnal voids (short term) (subgroup nocturnal polyuria).Comparison 4 Desmopressin plus alpha‐blocker versus alpha‐blocker, Outcome 3 Quality of life (short term) (subgroup route and dose).Comparison 4 Desmopressin plus alpha‐blocker versus alpha‐blocker, Outcome 4 Quality of life (short term) (subgroup nocturnal polyuria).Comparison 4 Desmopressin plus alpha‐blocker versus alpha‐blocker, Outcome 5 Major adverse events (short term) (subgroup route and dose).Comparison 4 Desmopressin plus alpha‐blocker versus alpha‐blocker, Outcome 6 Major adverse events (short term) (subgroup nocturnal polyuria).Comparison 4 Desmopressin plus alpha‐blocker versus alpha‐blocker, Outcome 7 Minor adverse events (short term).Comparison 4 Desmopressin plus alpha‐blocker versus alpha‐blocker, Outcome 8 Treatment withdrawal due to adverse event (short term).Comparison 5 Desmopressin plus alpha‐blocker versus alpha‐blocker plus anticholinergic, Outcome 1 Number of nocturnal voids (short term).Comparison 5 Desmopressin plus alpha‐blocker versus alpha‐blocker plus anticholinergic, Outcome 2 Major adverse events (short term).Comparison 5 Desmopressin plus alpha‐blocker versus alpha‐blocker plus anticholinergic, Outcome 3 Minor adverse events (short term).Comparison 5 Desmopressin plus alpha‐blocker versus alpha‐blocker plus anticholinergic, Outcome 4 Treatment withdrawal due to adverse event (short term).